Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health and Salix Pharmaceuticals announced the presentation of their RED-C Phase 3 clinical trial program at AASLD. The study evaluates a next-generation soluble solid dispersion (SSD) immediate-release rifaximin product designed to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization in cirrhosis patients. The program consists of two global Phase 3 trials involving over 1,000 patients across 398 study sites in 17 countries. Patient enrollment is complete, with efficacy and safety results pending. The therapeutic aims to enhance gastrointestinal luminal solubility while limiting systemic exposure, addressing an unmet medical need as there are currently no approved medications for primary prophylaxis of OHE in cirrhosis.

Bausch Health Canada announced positive reimbursement recommendations from Canada's Drug Agency (CDA) and Quebec's INESSS for PrCABTREO, their triple-combination topical treatment for acne vulgaris. The gel, containing clindamycin phosphate, adapalene, and benzoyl peroxide, is approved for patients 12 years and older. As the first and only triple-combination topical acne treatment approved by Health Canada, CABTREO combines three mechanisms of action. The company will now work with the pan-Canadian Pharmaceutical Alliance to finalize reimbursement terms for Canada's public drug plans. The prescription therapy is currently available through pharmacies across Canada.

Bausch Health (BHC) reported strong Q3 2024 results with consolidated revenues of $2.51 billion, up 12% year-over-year, marking the sixth consecutive quarter of growth. The company achieved organic revenue growth of 9%, with all segments showing positive performance. Despite a GAAP net loss of $85 million, Adjusted EBITDA increased 10% to $909 million. Notable segment performances included Bausch + Lomb (+19%), Solta Medical (+35%), and Salix (+5%). Based on these results, BHC raised its full-year 2024 guidance, projecting revenues between $9.500-$9.675 billion and Adjusted EBITDA of $3.275-$3.375 billion.

Bausch Health announced upcoming presentations at the American College of Gastroenterology 2024 Annual Scientific Meeting, featuring key analyses of Xifaxan and Plenvu. The main highlight is a Presidential Plenary presentation comparing Xifaxan monotherapy to lactulose monotherapy in reducing overt hepatic encephalopathy (OHE) recurrence and mortality. Additional research includes data on Xifaxan's impact on OHE rehospitalizations in commercial and Medicare patients, and Plenvu's efficacy as a bowel preparation medication in patients with comorbid conditions or taking medications affecting bowel prep quality.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) has announced that it will release its third quarter 2024 financial results after market close on Wednesday, October 30, 2024. The company will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update.

All materials related to the financial results will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call. Interested parties can access the webcast through the company's website. A replay of the conference call will also be available on the investor relations website for those unable to attend the live event.

To participate in the live Q&A session, individuals must register using a provided link to receive confirmation and further details via email.

Bausch Health and Salix have released the Liver Health Trends Report in Action, highlighting the urgent need for improved understanding of liver disease across healthcare providers. The report reveals that care for chronic liver disease (CLD) patients is increasingly falling on non-specialists who require better education and support.

Key findings include:

• Approximately 4.5 million U.S. adults are diagnosed with CLD, which can lead to cirrhosis
• CLD is the tenth leading cause of death in the U.S., with mortality projected to nearly triple by 2030
• People with cirrhosis have nearly double the post-emergency department visit mortality rate compared to chronic heart failure patients

The report calls for holistic, multi-disciplinary treatment approaches, consistent use of non-invasive screening tools, and better education to identify at-risk patients sooner. It also emphasizes the need for broader adoption of user-friendly guidelines, investment in community-based care resources, and increased awareness of screening guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD).

Health Canada has approved CABTREO, a new triple-combination topical treatment for acne vulgaris in patients 12 years and older. Developed by Bausch Health (NYSE:BHC, TSX:BHC), CABTREO is the first and only triple-combination topical acne treatment approved in Canada, combining an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The once-daily gel has shown significant success in reducing both inflammatory and non-inflammatory acne lesions. CABTREO will be available in Canadian pharmacies in Q4 2024, offering a new option for millions of Canadians affected by acne.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, have announced the recipients of the 2024 Salix Gastrointestinal Health Scholars Program. For the fifth consecutive year, 10 students living with GI diseases will each receive a $10,000 scholarship to support their higher education. The awardees were selected from over 275 applications across four categories: Undergraduate Scholar Awards, Graduate Scholar Awards, Single Parent's Scholar Award, and Working Parent's Scholar Award.

The program aims to assist students who balance their academic pursuits with GI challenges. Applicants submitted essays describing their experiences and the role of their healthcare providers in their educational journey. An independent panel of judges reviewed all applications.

Bausch Health (NYSE:BHC) reported strong Q2 2024 results, with consolidated revenues of $2.40 billion, up 11% on a reported basis and 8% organically. The company achieved a GAAP Net Income of $10 million and Adjusted EBITDA of $798 million, up 10%. Key highlights include:

- Xifaxan® revenues grew 10% in the Salix segment
- International segment revenues increased 7%, with strong growth in Canada and Latin America
- Solta Medical segment revenues rose 16%, driven by growth in Asia-Pacific
- Bausch + Lomb segment revenues increased 17%, with organic growth across all business units

The company has raised its full-year Revenue and Adjusted EBITDA guidance. Bausch Health continues to focus on advancing its R&D pipeline, strengthening its balance sheet, and executing commercial strategies for global growth.